2. Academic Validation
  3. Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

  • J Med Chem. 2021 Aug 12;64(15):11614-11636. doi: 10.1021/acs.jmedchem.1c00957.
Damian Muszak 1,  Ewa Surmiak 1,  Jacek Plewka 2,  Katarzyna Magiera-Mularz 1,  Justyna Kocik-Krol 1,  Bogdan Musielak 1,  Dominik Sala 1,  Radoslaw Kitel 1,  Malgorzata Stec 3,  Kazimierz Weglarczyk 3,  Maciej Siedlar 3,  Alexander Dömling 4,  Lukasz Skalniak 1,  Tad A Holak 1
Affiliations

Affiliations

  • 1 Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland.
  • 2 Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387 Kraków, Poland.
  • 3 Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, 30-663 Krakow, Poland.
  • 4 Department of Drug Design, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
PMID: 34313116 DOI: 10.1021/acs.jmedchem.1c00957
Abstract

We describe a new class of potent PD-L1/PD-1 inhibitors based on a terphenyl scaffold that is derived from the rigidified biphenyl-inspired structure. Using in silico docking, we designed and then experimentally demonstrated the effectiveness of the terphenyl-based scaffolds in inhibiting PD-1/PD-L1 complex formation using various biophysical and biochemical techniques. We also present a high-resolution structure of the complex of PD-L1 with one of our most potent inhibitors to identify key PD-L1/inhibitor interactions at the molecular level. In addition, we show the efficacy of our most potent inhibitors in activating the antitumor response using primary human immune cells from healthy donors.

Figures
Products